| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2006 | CA2575339A1 Substituted n-acyl-2-aminothiazoles |
| 02/09/2006 | CA2575334A1 Use of methyl pyruvate for the purpose of increasing muscle energy production |
| 02/09/2006 | CA2575330A1 Compositions and methods for nutrition supplementation |
| 02/09/2006 | CA2575329A1 Indole, indazole or indoline derivatives |
| 02/09/2006 | CA2575216A1 Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| 02/09/2006 | CA2575204A1 Methods of treating ophthalmic conditions |
| 02/09/2006 | CA2575119A1 Methods and compositions for reducing toxicity associated with leflunomide treatment |
| 02/09/2006 | CA2575018A1 Benzyloxy derivatives as maob inhibitors |
| 02/09/2006 | CA2574966A1 Isoindoline compounds and methods of their use |
| 02/09/2006 | CA2574958A1 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| 02/09/2006 | CA2574956A1 Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| 02/09/2006 | CA2574925A1 Pharmaceutical dosage forms including rasagiline |
| 02/09/2006 | CA2574767A1 Particulate constructs for release of active agents |
| 02/09/2006 | CA2574737A1 Compounds and compositions as modulators of steroid hormone nuclear receptors |
| 02/09/2006 | CA2574626A1 Antiplatelet agent and process for producing the same |
| 02/09/2006 | CA2574555A1 Phenytoin formulations, and uses thereof in wound healing |
| 02/09/2006 | CA2574400A1 Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| 02/09/2006 | CA2574303A1 Modafinil oral lyophilizate |
| 02/09/2006 | CA2574218A1 Substituted amide beta secretase inhibitors |
| 02/09/2006 | CA2574176A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | CA2574147A1 Substituted pyrazoles, compositions containing such compounds and methods of use |
| 02/09/2006 | CA2574121A1 Antiviral compounds |
| 02/09/2006 | CA2573869A1 Generic probes for the detection of phosphorylated sequences |
| 02/09/2006 | CA2573741A1 Use of organic glucosamine salts |
| 02/09/2006 | CA2573573A1 Fused ring heterocycle kinase modulators |
| 02/09/2006 | CA2573398A1 Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides |
| 02/09/2006 | CA2573362A1 Pyrrolo-pyridine kinase modulators |
| 02/09/2006 | CA2573338A1 A nutritional composition comprising dried fruit solids and an oligosaccharide and its use for treating osteoporosis |
| 02/09/2006 | CA2573198A1 Nicotinamide derivatives and their use as therapeutic agents |
| 02/09/2006 | CA2573124A1 Anti-inflammatory medicaments |
| 02/09/2006 | CA2573103A1 Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| 02/09/2006 | CA2573063A1 Compounds useful for inhibiting chk1 |
| 02/09/2006 | CA2573000A1 Composition containing statins and omega-3 fatty acids |
| 02/09/2006 | CA2572962A1 Compositions and methods relating to novel compounds and targets thereof |
| 02/09/2006 | CA2572740A1 Alkyl-and piperidine-substituted benzimidazole-derivates |
| 02/09/2006 | CA2572618A1 Taxol immunoassay |
| 02/09/2006 | CA2572544A1 Modified pyrimidine glucocorticoid receptor modulators |
| 02/09/2006 | CA2572331A1 C-met modulators and method of use |
| 02/09/2006 | CA2571937A1 Pyrimidine derivatives useful as inhibitors of pkc-theta |
| 02/09/2006 | CA2571789A1 Indoles having anti-diabetic activity |
| 02/09/2006 | CA2571786A1 Prostaglandin analogs |
| 02/09/2006 | CA2571726A1 Prodrugs of hiv protease inhibitors |
| 02/09/2006 | CA2571405A1 Composition and method for treating hemorrhoids and/or anorectal disorders |
| 02/09/2006 | CA2571377A1 Cyclic progestin regimens and kits |
| 02/09/2006 | CA2569479A1 Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 02/09/2006 | CA2555566A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/08/2006 | EP1624068A1 Genetic immunization with cationic lipids |
| 02/08/2006 | EP1624064A2 Nucleic acids and proteins from streptococcus pneumoniae |
| 02/08/2006 | EP1624063A2 Chimeric gene encoding the antigenic determinants of four proteins of L. infantum |
| 02/08/2006 | EP1623990A2 Compositions and methods for the treatment of tumours |
| 02/08/2006 | EP1623989A1 Compositions and methods for the diagnosis of tumours |
| 02/08/2006 | EP1623987A1 Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines |
| 02/08/2006 | EP1623986A1 Use of vinca alkaloid and its salt |
| 02/08/2006 | EP1623985A2 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents |
| 02/08/2006 | EP1623984A1 Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt |
| 02/08/2006 | EP1623983A1 Heterocyclic compounds useful as DPP-IV inhibitors |
| 02/08/2006 | EP1623981A1 Anti-leishmania agent |
| 02/08/2006 | EP1623974A1 2"-hydroxynicotianamine, process for producing the same and angiotensin converting enzyme inhibitor, hypotensive drug and health food |
| 02/08/2006 | EP1623741A2 Cannabinoid receptor ligands for hair growth modulation |
| 02/08/2006 | EP1623740A1 Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits |
| 02/08/2006 | EP1623721A1 Effector cell function inhibitor |
| 02/08/2006 | EP1623714A2 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases |
| 02/08/2006 | EP1623713A1 Cominations of pure anti-estrogen with aromatase inhibitors |
| 02/08/2006 | EP1623712A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or analogues |
| 02/08/2006 | EP1623711A1 External patch containing estrogen and/or progestogen |
| 02/08/2006 | EP1623709A1 Remedy for rheumatoid arthritis |
| 02/08/2006 | EP1623708A2 Pharmaceutical composition comprising acetyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 02/08/2006 | EP1623707A1 Medicinal composition for treating sudden deafness |
| 02/08/2006 | EP1623706A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 02/08/2006 | EP1623705A1 Use of phenylethanolaminotetralines for preparing anxiolytic drugs |
| 02/08/2006 | EP1623704A1 Therapeutic agent |
| 02/08/2006 | EP1623703A1 Controlled release hydrocodone formulations |
| 02/08/2006 | EP1623046A2 Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| 02/08/2006 | EP1622959A2 Process of making press molded materials using heat activated tertiary amine urethane catalysts |
| 02/08/2006 | EP1622935A2 Spex compositions and methods of use |
| 02/08/2006 | EP1622926A2 Novel method and intermediates for the preparation of 19-nor-steroids-17-halogen compounds |
| 02/08/2006 | EP1622925A2 Novel method and intermediates for the preparation of 19-nor-steroid compounds |
| 02/08/2006 | EP1622924A2 8$g(b)-vinyl-11$g(b)-( g(v)-substituted)alkyl-estra-1,3,5(10)-trienes |
| 02/08/2006 | EP1622922A2 Derivatives of azithromycin |
| 02/08/2006 | EP1622916A2 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| 02/08/2006 | EP1622914A2 New piperidinylamino-thieno 2,3-d pyrimidine compounds |
| 02/08/2006 | EP1622911A2 Pyrrolo[1,2-b]pyridazine compounds and their use as crf-1 receptor antagonists |
| 02/08/2006 | EP1622909A1 Cannabinoid receptor ligands and uses thereof |
| 02/08/2006 | EP1622907A1 Azabicyclononene derivatives |
| 02/08/2006 | EP1622906A1 Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| 02/08/2006 | EP1622904A1 Cannabinoid receptor ligands and uses thereof |
| 02/08/2006 | EP1622903A1 Cannabinoid receptor ligands and uses thereof |
| 02/08/2006 | EP1622894A1 Antitumoral antiadrogenic pyrrolidines |
| 02/08/2006 | EP1622884A1 New heterocyclic amides exhibiting an inhibitory activity at the vanilloid receptor 1 (vr1). |
| 02/08/2006 | EP1622883A2 Compounds, compositions, and methods |
| 02/08/2006 | EP1622878A2 Compounds, compositions and methods |
| 02/08/2006 | EP1622870A2 Glutaminyl based dp iv-inhibitors |
| 02/08/2006 | EP1622869A1 Glyoxalase inhibitors |
| 02/08/2006 | EP1622867A1 N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists |
| 02/08/2006 | EP1622866A1 Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| 02/08/2006 | EP1622860A1 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
| 02/08/2006 | EP1622856A2 Heat activated tertiary amine urethane catalysts |
| 02/08/2006 | EP1622685A1 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors |
| 02/08/2006 | EP1622684A2 Compositions and methods relating to novel compounds and targets thereof |
| 02/08/2006 | EP1622660A2 Novel methods for administration of drugs and devices useful thereof |